Opus Genetics (IRD) News Today $0.98 -0.04 (-4.25%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.96 -0.01 (-1.19%) As of 06/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IRD Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Opus Genetics (NASDAQ:IRD) Earns "Buy" Rating from HC WainwrightJune 29 at 2:01 AM | americanbankingnews.comOpus Genetics (NASDAQ:IRD) Cut to "Sell" at Wall Street ZenJune 28 at 3:49 AM | americanbankingnews.comOpus Genetics (NASDAQ:IRD) Stock Rating Lowered by Wall Street ZenJune 28 at 3:15 AM | marketbeat.comHC Wainwright Reiterates Buy Rating for Opus Genetics (NASDAQ:IRD)June 27 at 8:07 AM | marketbeat.comOpus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaJune 26, 2025 | globenewswire.comOpus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK ProgramJune 23, 2025 | globenewswire.comOpus Genetics (NASDAQ:IRD) Trading 1% Higher - What's Next?June 6, 2025 | marketbeat.comOpus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under ...June 4, 2025 | seekingalpha.comIRD Opus Genetics, Inc.June 3, 2025 | seekingalpha.comOpus Genetics Shares Rise After Positive Trial Results for Eye TreatmentJune 2, 2025 | marketwatch.comOpus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast ConditionsJune 2, 2025 | globenewswire.comOpus Genetics, Inc. (NASDAQ:IRD) Just Reported First-Quarter Earnings And Analysts Are Lifting Their EstimatesMay 18, 2025 | finance.yahoo.comOpus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate UpdateMay 15, 2025 | globenewswire.comOpus Genetics to Present Advances in Gene Therapy for Inherited Retinal Diseases at Major Scientific Conferences in May 2025May 13, 2025 | nasdaq.comOpus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in MayMay 12, 2025 | globenewswire.comOpus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy CandidateMay 6, 2025 | globenewswire.comOpus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful VisionMay 5, 2025 | globenewswire.comOpus Genetics shareholders approve key proposalsMay 3, 2025 | investing.comPRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George MagrathApril 15, 2025 | markets.businessinsider.comCraig-Hallum Initiates Coverage of Opus Genetics (IRD) with Buy RecommendationApril 12, 2025 | msn.comCraig-Hallum bullish on Opus Genetics, initiates with a BuyApril 11, 2025 | markets.businessinsider.comOpus Genetics initiated with a Buy at Craig-HallumApril 11, 2025 | markets.businessinsider.comFounder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance ConcernsApril 11, 2025 | globenewswire.comOpus Genetics announces data from patient in Phase 1/2 trial of OPGx-LCA5April 8, 2025 | markets.businessinsider.comOpus Genetics urges stockholders to vote for company’s nine board nomineesApril 8, 2025 | markets.businessinsider.comOpus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal DiseasesApril 8, 2025 | globenewswire.comOpus Genetics Files Definitive Proxy Statement and Sends Letter to Stockholders Highlighting the Company’s Transformation and ProgressApril 7, 2025 | markets.businessinsider.comParty Time: Brokers Just Made Major Increases To Their Opus Genetics, Inc. (NASDAQ:IRD) Earnings ForecastsApril 5, 2025 | finance.yahoo.comOpus Genetics Terminates Purchase Agreement with Lincoln ParkApril 4, 2025 | tipranks.comOpus Genetics price target lowered to $8 from $9 at JonesResearchApril 2, 2025 | markets.businessinsider.comOpus Genetics to Participate in Upcoming Investor Conference in AprilApril 2, 2025 | globenewswire.comOpus Leans Lower on Year-End FiguresMarch 31, 2025 | baystreet.caOpus Genetics reports FY24 EPS ($2.15) vs. (46c) last yearMarch 31, 2025 | markets.businessinsider.comOpus Genetics Announces Financial Results for Full Year 2024March 31, 2025 | globenewswire.comSeveral Insiders Invested In Opus Genetics Flagging Positive NewsMarch 26, 2025 | finance.yahoo.comOpus Genetics presents data on phentolamine ophthalmic solution 0.75%March 22, 2025 | markets.businessinsider.comOpus Genetics prices 21.05M shares at 95c in public offeringMarch 22, 2025 | markets.businessinsider.comRestore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus GeneticsMarch 21, 2025 | globenewswire.comOpus Genetics grants stock options to new employeesMarch 21, 2025 | investing.comOpus Genetics Approves Equity Awards for New Employees Under 2021 Inducement PlanMarch 21, 2025 | nasdaq.comOpus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IXMarch 21, 2025 | globenewswire.comOpus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 MillionMarch 21, 2025 | globenewswire.comOpus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 19, 2025 | globenewswire.comOpus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 MeetingMarch 6, 2025 | markets.businessinsider.comOpus Genetics announces presentations at ARVO 2025 meetingMarch 6, 2025 | markets.businessinsider.comOpus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 MeetingMarch 5, 2025 | globenewswire.comOpus Genetics gets FDA Fast Track designation for Phentolamine Ophthalmic SolutionFebruary 26, 2025 | msn.comOpus Genetics gets Fast Track designation for phentolamine ophthalmic solutionFebruary 26, 2025 | markets.businessinsider.comOpus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% ProgramsFebruary 26, 2025 | globenewswire.comOpus Genetics Inc (IRD)February 25, 2025 | investing.com Get Opus Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for IRD and its competitors with MarketBeat's FREE daily newsletter. Email Address IRD Media Mentions By Week IRD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IRD News Sentiment▼0.280.93▲Average Medical News Sentiment IRD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IRD Articles This Week▼82▲IRD Articles Average Week Get Opus Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for IRD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Semper Paratus Acquisition News biote News Inhibrx Biosciences News Design Therapeutics News Esperion Therapeutics News Nanobiotix News MediWound News Cardiff Oncology News I-Mab News ProQR Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IRD) was last updated on 6/30/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… And it's all thanks to President Trump. His ...InvestorPlace | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored“Trump’s 24-Hour Profit Windows” revealedTrading legend Larry Benedict has discovered a repeating surge of $240 billion (and more)... Flowing into a...Brownstone Research | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opus Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opus Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IRD Stock Alerts